Esperion receives five year patent extension for bempedoic acid

Esperion announced today that the U.S. Patent and Trademark Office, USPTO, issued a U.S. Patent Term Extension, PTE, certificate for bempedoic acid, which is contained in NEXLETOL Tablets and NEXLIZET Tablets. The certificate extends the term of U.S. Patent No. 7,335,799 by five years through December 3, 2030. The PTE certificate was granted under the patent restoration provisions of the Drug Price Competition and Patent Term Restoration Act of 1984. This PTE will be listed in Approved Drug Products with Therapeutic Equivalence Evaluations, published by the U.S. Food and Drug Administration.